Celleron licenses AZ's HDAC blocker
Celleron Therapeutics has secured exclusive rights to Anglo-Swedish drug major AstraZeneca's lead histone deacetylase inhibitor (AZD 9468), for global development in conjunction with its proprietary CancerNav predictive biomarker platform, which identifies tumors that are most likely to respond to an individual cancer drug.
Celleron will lead the cancer trial program and plans to use CancerNav to identify tumors that undergo a favorable response to the drug, potentially allowing for much more rapid development and market entry. Full rights to CXD101 pass to Celleron, including the right to sublicense. In return, AstraZeneca will receive milestones and royalties and may also re-aquire the compound at a later date. Further financial terms were not disclosed.
HDACs control a wide variety of mechanisms involved with tumor cell growth and division, and HDAC blockers represent a new class of cancer drugs. However, because HDACs are ubiquitously expressed, their clinical utility has been difficult to determine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze